 |
|
|
|
 |
Biaxin (Clarithromycin)-Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
[Protocol 07-038]
- Full Title :
- BIAXIN (CLARITHROMYCIN)-BASED ANTIBIOTIC THERAPY IN PREVIOUSLY UNTREATED, ADVANCED STAGE INDOLENT LYMPHOMA
- Purpose :
Indolent B-cell non-Hodgkin's lymphomas are a group of slow-growing cancers of the immune system that may not be in need of immediate treatment. Patients with these diseases can be monitored on a regular basis without initial treatment. The purpose of this study is to see if treatment with the antibiotic clarithromycin (Biaxin), given by mouth for 3 months, can shrink or delay the growth of previously untreated advanced indolent lymphoma.
Investigators would also like to see how clarithromycin works on lymphoma and blood cells. There is some evidence that this medication may change the behavior of lymphocytes (white blood cells), in addition to its known activity against bacterial infections. Patients will be asked to have their blood tested before, during, and after treatment so researchers can answer this question in the laboratory.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of advanced stage indolent non-Hodgkin's lymphoma (follicular lymphoma, small lymphocytic lymphoma, or marginal zone lymphoma) that has not been treated.
- Patients must not be allergic to clarithromycin and may not have taken it during the 6 months prior to entering the study.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. Carol Portlock at 212-639-8109.
|
|
|
|
|
